



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

May 11, 2021

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip code: 500672

Sub.: 1. Intimation regarding re-scheduling of the meeting of the Board of Directors of Novartis India Limited (“the Company”)

2. Intimation regarding extension in the Closure of Trading Window

Ref.: 1. Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

2. Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015

Dear Sir/ Madam,

This is further to our letter dated March 31, 2021 with respect to the intimation of the meeting of the Board of Directors of the Company scheduled to be held on Thursday, May 20, 2021. In that regard, this is to inform that the said Board Meeting of the Company has been re-scheduled and will now be held on Thursday, June 17, 2021, to *inter alia* consider the Audited financial results of the Company for the fourth quarter and financial year ending on March 31, 2021 ("said results") and recommendation of final dividend on Equity Share, if any, for the said year.

In this connection, further note that pursuant to the Company's Code of Conduct to regulate, monitor and report share trading by Insiders ["the Code"], the trading window for dealing in securities of the Company which was earlier closed from Thursday, April 1, 2021 to Saturday, May 22, 2021 (both days inclusive) shall continue to remain closed till Saturday, June 19, 2021.

This is for your information.

Thanking You.

Yours sincerely,

For Novartis India Limited

Trivikram Guda
Company Secretary & Compliance Officer